Clinical Research Directory

Inclusion Criteria: * Subject has Idiopathic PD defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor or rigidity and without any other known or suspected cause of Parkinsonism (according to Movement disorder society (MDS) clinical diagnostic criteria for Parkinson's disease confirmed by a fellowship trained movements disorder specialist * Subject is Hoehn \& Yahr stage 2 to 3 * Subject has a Montreal Cognitive Assessment (MOCA) score ≥26. * Subject is \> 45 and \<90 years of age. * proficient in speaking, reading, and understanding English * capable of providing informed written consent * Subject is on a stable dose (at least 1 month prior to baseline visit) of antiparkinsonian agents and willing to remain on this dose for the duration of the study. If on a cholinesterase inhibitor, a stable dose without changes for 1 month is required. * Subject has undergone a brain CT or MRI prior to rule out underlying structural lesions Exclusion criteria: * Subject has atypical Parkinson's syndrome(s) due to drugs, metabolic neurogenetic disorders (e.g., Wilson's Disease), encephalitis, cerebrovascular disease, or degenerative disease (e.g., Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Lewy Body dementia) * history of any psychiatric illness that would pose a safety risk * diagnosis of dementia or other neurological conditions * currently taking sedative medications that are clinically contraindicated * has undergone recent change (\<1 month) in medication * recent drug or alcohol abuse or dependence * laboratory results the would pose safety risk * concurrently or has participated in other clinical trial investigation within 3 months * pregnant * no healthcare * history of epilepsy, stroke, or seizure in past 24 months * diagnosis of migraines * have certain implantable medical devices * contraindications for MRI * life expectancy of less than 2 years